The Prostate Cancer Clinical Trials Consortium (PCCTC)

The Prostate Cancer Clinical Trials Consortium (PCCTC) has created a new paradigm in collaborative drug development, fostering a culture of transparent project co-development through its unique infrastructure and committed team of research professionals. Its comprehensive suite of contract research organization (CRO) services and world-class scientific expertise streamline and accelerate the activation, accrual, and completion of multicenter clinical trials. The PCCTC is changing how prostate cancer drugs are developed. Their unique infrastructure facilitates project co-development between investigators, clinical research sites, and industry partners.

Mission

The PCCTC’s distinguished investigators work together on a single mission: to design, implement, and complete hypothesis-driven early phase trials in prostate cancer, translating scientific discoveries to

Research Areas

- Tool Development
  - Clinical Trial
- Biomarker Research
  - Drug
- Data-Sharing Enabler
- Product Development
  - Drugs

At a Glance

- Status: Active Consortium
- Year Launched: 2005
- Initiating Organization: The Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP)
- Initiator Type: Nonprofit foundation
- Location: North America

Abstract

The PCCTC has created a new paradigm in collaborative drug development, fostering a culture of transparent project co-development through its unique infrastructure and committed team of research professionals. Its comprehensive suite of contract research organization (CRO) services and world-class scientific expertise streamline and accelerate the activation, accrual, and completion of multicenter clinical trials. The PCCTC is changing how prostate cancer drugs are developed. Their unique infrastructure facilitates project co-development between investigators, clinical research sites, and industry partners.
improved standards of care. They offer services to carry out this mission ensuring efficient trial selection, reporting, site management, clinical operations, and data analyses.

Consortium History

The Prostate Cancer Clinical Trials Consortium (PCCTC) was initiated in 2005 by the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP) in response to critically unmet needs in prostate cancer clinical research identified by physician investigators and patient advocates. To fulfill the mission, it developed a unique infrastructure which has fostered a culture of transparent project co-development between investigators, research sites, and industry partners. Established as an independent entity in 2014, the PCCTC, LLC is now the nation’s premier multicenter clinical research organization specializing in cutting-edge prostate cancer research. Through the collaborative nature and intellectual synergy of their leadership, the PCCTC remains poised to make a significant impact on the lives of patients by keeping the pipeline primed with the most promising novel agents and validated biomarkers.

Structure & Governance

The Consortium is led by a Management Team, a Board of Managers, and a Scientific Oversight Committee.

Financing

Funding is provided by the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP).

Impact/Accomplishment
For current and past news relating to the PCCTC, click here

Links/Social Media Feed

Homepage  http://pcctc.org/
Twitter  @ThePCCTC

Points of Contact

http://pcctc.org/contact/

Sponsors & Partners

Memorial Sloan Kettering Cancer Center
Dana-Faber/Harvard Cancer Center
Duke Comprehensive Cancer Center
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Oregon Health and Science University Knight Cancer Institute
University of California San Francisco Helen Diller Family Cancer Center
University of Washington Fred Hutchinson Cancer Research Center
University of Wisconsin Carbone Cancer Center
Wayne State University/Karamanos Cancer Institute
UCLA Jonsson Comprehensive Cancer Center

Updated: 06/27/2017